Media About Us


  • 28 May 2013

    Prescription drugs with nanotechnology. Americans to build a pharmaceutical plant in Kaluga

    Prescription drugs with nanotechnology. Americans to build a pharmaceutical plant in Kaluga

    Yulia Kostina, Smart News

    NovaMedica, a joint venture of Domain Associates and RusnanoMedInvest, will complement the pharmaceutical cluster in Kaluga region. A projected plant will be specializing in the manufacturing of therapeutics and medicines for kids. The plant’s capacity is 200 Mio tablets and 5 Mio ampules a year.

  • 27 May 2013

    Tablets from Kaluga

    Tablets from Kaluga

    Maria Dranishnikova, Vedomosti

    “NovaMedica, LLC plans to build a plant at the site of Kaluga pharmaceutical cluster”, - told Vladimir Gurdus, Team Drive (project managing company) member of the Board while present at the Russian pharmaceutical forum, organized by Adam Smith Institute.

  • 29 March 2013

    Russian investment vehicle sets sights on innovative drugs

    Russian investment vehicle sets sights on innovative drugs

    Eugene Gerden, Chemistry World

    Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. Rusnano has been ploughing hundreds of millions of dollars into pioneering pharma companies with the aim of growing Russia’s domestic drug production, and making a tidy return by licensing drugs to foreign partners.

  • 04 February 2013

    Russia is becoming a player in global biopharma

    Russia is becoming a player in global biopharma

    Business New Europe (bne)

    A biotechnology revolution is gathering steam in Russia, spurred by state investment programs, a host of cross-border partnerships and a domestic market that international investors find highly attractive. The government is modernizing a decaying healthcare system by building new hospitals and introducing innovative technologies.

  • 20 December 2012

    Russia fund in consortium to back U.S. pharma firms

    Russia fund in consortium to back U.S. pharma firms

    Megan Davies, Reuters

    Russian state technology firm Rusnano, alongside a group of investors, is investing $93 million in three U.S.-based pharmaceutical firms to develop drugs to treat illnesses such as epilepsy, the investors said on Wednesday.

  • 25 July 2012

    Venture capital spurs Russian drug development  in California

    Venture capital spurs Russian drug development in California

    Isabel Gorst, FT-Beyondbrics

    When the Kremlin invited a group of US venture capitalists to Russia during the financial crisis, some of the visitors saw as much an opportunity to scout for fresh sources of capital as they did a new place to invest in.

  • 25 July 2012

    Rusnano and Domain Associates announce first joint investment

    Rusnano and Domain Associates announce first joint investment

    Nano werk

    RusnanoMedInvest (RMI, a portfolio company of RUSNANO) and Domain Associates, the Princeton, NJ- and San Diego, CA-based venture capital firm today announced their first investment under a joint agreement reached in March. The two will jointly invest nearly $40 million in San Diego, CA-based, CoDa Therapeutics, a Domain portfolio company, along with current investors GBS Ventures (Melbourne, Australia) and BioPacificVentures (Auckland, NZ).

  • 25 July 2012

    Coda Therapeutics raise additional $20M for series B

    Private Equity Hub

    CoDa Therapeutics has raised an additional $20 million from RusnanoMedInvest in a second close of its Series B financing round. This brings the total Series B Round to nearly $40 million following the first close late last year. All current investors, including Domain Associates, GBS Ventures and BioPacificVentures participated. San Diego-based CoDa is a biopharmaceutical company working to develop drug therapies for wounds that do not heal properly, including venous leg and diabetic foot ulcers.

  • 24 July 2012

    Russias Rusnano, Domain Invest $40 Million In San Diegos CoDa

    Russias Rusnano, Domain Invest $40 Million In San Diegos CoDa

    Ksenia Galouchko, Bloomberg

    Russian Nanotechnologies, the state- run technology holding, and Domain Associates, a U.S. venture fund, are investing about $40 million in San Diego-based biopharmaceutical company CoDa Therapeutics.

  • 07 March 2012

    RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects

    RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects

    Nanowerk News

    RUSNANO and Domain Associates, a U.S. venture capital firm specializing in leading-edge life sciences technologies, today announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.